CL2019003843A1 - Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas. - Google Patents

Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas.

Info

Publication number
CL2019003843A1
CL2019003843A1 CL2019003843A CL2019003843A CL2019003843A1 CL 2019003843 A1 CL2019003843 A1 CL 2019003843A1 CL 2019003843 A CL2019003843 A CL 2019003843A CL 2019003843 A CL2019003843 A CL 2019003843A CL 2019003843 A1 CL2019003843 A1 CL 2019003843A1
Authority
CL
Chile
Prior art keywords
protein
recombinant viral
human cells
genetic material
viral particles
Prior art date
Application number
CL2019003843A
Other languages
English (en)
Inventor
Andrew J Murphy
Christos Kyratsous
Christopher Schoenherr
Leah Sabin
Aris N Economides
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63080488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003843(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2019003843A1 publication Critical patent/CL2019003843A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EN LA PRESENTE DESCRIPCIÓN SE PROPORCIONAN COMPOSICIONES Y MÉTODOS PARA REORIENTAR PARTÍCULAS DE CÁPSIDAS VIRALES RECOMBINANTES A TRAVÉS DE UN PAR DE UNIÓN PROTEÍNA:PROTEÍNA ESPECÍFICO QUE FORMA UN ENLACE COVALENTE, POR EJEMPLO, ISOPEPTÍDICO, PARA MOSTRAR UN LIGANDO DE ORIENTACIÓN SOBRE LA PROTEÍNA DE CÁPSIDA, EN DONDE EL LIGANDO DE ORIENTACIÓN SE UNE ESPECÍFICAMENTE A UN MARCADOR DE SUPERFICIE CELULAR EXPRESADO EN LA CÉLULA DE INTERÉS.
CL2019003843A 2017-06-27 2019-12-26 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas. CL2019003843A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762525708P 2017-06-27 2017-06-27

Publications (1)

Publication Number Publication Date
CL2019003843A1 true CL2019003843A1 (es) 2020-07-24

Family

ID=63080488

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019003843A CL2019003843A1 (es) 2017-06-27 2019-12-26 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas.
CL2020003438A CL2020003438A1 (es) 2017-06-27 2020-12-30 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas (divisional de la solicitud no. 201903843)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020003438A CL2020003438A1 (es) 2017-06-27 2020-12-30 Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas (divisional de la solicitud no. 201903843)

Country Status (28)

Country Link
US (1) US20200140492A1 (es)
EP (2) EP4219529A1 (es)
JP (3) JP2020525020A (es)
KR (1) KR20200021987A (es)
CN (2) CN116891534A (es)
AU (2) AU2018290885B2 (es)
BR (1) BR112019027866A2 (es)
CA (1) CA3066950A1 (es)
CL (2) CL2019003843A1 (es)
CO (1) CO2019014684A2 (es)
CY (1) CY1126149T1 (es)
DK (1) DK3645553T5 (es)
ES (1) ES2943020T3 (es)
FI (1) FI3645553T3 (es)
HR (1) HRP20230538T1 (es)
HU (1) HUE061908T2 (es)
IL (1) IL271570A (es)
LT (1) LT3645553T (es)
MA (1) MA49514B1 (es)
MD (1) MD3645553T2 (es)
MX (2) MX2020000246A (es)
PH (1) PH12019550269A1 (es)
PL (1) PL3645553T3 (es)
PT (1) PT3645553T (es)
RS (1) RS64233B1 (es)
SG (1) SG11201911614XA (es)
SI (1) SI3645553T1 (es)
WO (1) WO2019006046A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
WO2019169144A1 (en) * 2018-02-28 2019-09-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education A modular system for gene and protein delivery based on aav
EP3774926A1 (en) 2018-04-05 2021-02-17 Bio-Rad ABD Serotec GmbH Display systems for proteins of interest
EP3942079A1 (en) 2019-03-18 2022-01-26 Bio-Rad ABD Serotec GmbH Protection of spytag-containing periplasmic fusion proteins from protease tsp and ompt degradation
PE20212357A1 (es) * 2019-05-24 2021-12-17 Regeneron Pharma Particulas virales modificadas y usos de estas
US20220306955A1 (en) * 2019-06-11 2022-09-29 Chevron U.S.A. Inc. Membranes for contaminant removal from natural gas and methods for use thereof
GB201915905D0 (en) * 2019-11-01 2019-12-18 Spybiotech Ltd Viruses with modified capsid proteins
US20230002451A1 (en) * 2019-11-08 2023-01-05 President And Fellows Of Harvard College Viral capsid polypeptides
CN114632148B (zh) * 2020-12-15 2024-08-09 榕森生物科技(北京)有限公司 病原样抗原疫苗及其制备方法
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
KR20240095211A (ko) 2021-11-04 2024-06-25 리제너론 파마슈티칼스 인코포레이티드 골격근에 재표적화된 바이러스 입자
CN114213505B (zh) * 2021-12-10 2022-09-20 和元生物技术（上海）股份有限公司 一种适用于特异感染u87-mg细胞的腺相关病毒突变体
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2024026494A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
US20240173426A1 (en) 2022-11-14 2024-05-30 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US20240167984A1 (en) 2022-11-18 2024-05-23 Regeneron Pharmaceuticals, Inc. Methods for detecting and determining protein structures and stability in fluids, including biological fluids
WO2024124019A2 (en) * 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1286981C (zh) 2004-11-30 2006-11-29 华中科技大学同济医学院附属同济医院 表达人类cyp2j2反义基因的重组腺相关病毒及其制备方法
EP2158211B1 (en) 2007-05-31 2016-08-10 Medigene AG Mutated structural protein of a parvovirus
CN102711449B (zh) 2009-12-10 2015-01-07 瑞泽恩制药公司 生产重链抗体的小鼠
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
AR094403A1 (es) * 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
WO2015143414A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
US20160018835A1 (en) * 2014-07-18 2016-01-21 Retroficiency, Inc. System and method for virtual energy assessment of facilities
EP3244915A1 (en) * 2015-01-15 2017-11-22 University of Copenhagen Virus-like particle with efficient epitope display
EP3262063B1 (en) 2015-02-26 2021-09-22 Var2 Pharmaceuticals ApS Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
EP3141600A1 (en) 2015-09-11 2017-03-15 Institut National de la Recherche Agronomique Nepovirus coat protein fusion polypeptides and their use
AU2017313917B2 (en) 2016-08-18 2023-12-21 The Regents Of The University Of California CRISPR-Cas genome engineering via a modular AAV delivery system
WO2019169144A1 (en) * 2018-02-28 2019-09-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education A modular system for gene and protein delivery based on aav

Also Published As

Publication number Publication date
LT3645553T (lt) 2023-04-25
PL3645553T3 (pl) 2023-07-17
CN110997699A (zh) 2020-04-10
FI3645553T3 (fi) 2023-05-22
EP3645553B1 (en) 2023-03-15
BR112019027866A2 (pt) 2020-07-07
MD3645553T2 (ro) 2023-07-31
PT3645553T (pt) 2023-05-08
IL271570A (en) 2020-02-27
WO2019006046A3 (en) 2019-02-14
HUE061908T2 (hu) 2023-09-28
JP2024071769A (ja) 2024-05-24
AU2018290885B2 (en) 2023-07-27
MX2023009051A (es) 2023-08-10
CL2020003438A1 (es) 2021-07-23
DK3645553T5 (da) 2024-08-26
CA3066950A1 (en) 2019-01-03
DK3645553T3 (da) 2023-05-22
MA49514B1 (fr) 2023-06-28
EP3645553A2 (en) 2020-05-06
US20200140492A1 (en) 2020-05-07
AU2018290885A1 (en) 2020-01-16
PH12019550269A1 (en) 2021-01-11
EP4219529A1 (en) 2023-08-02
JP2022186991A (ja) 2022-12-15
CY1126149T1 (el) 2023-11-15
SI3645553T1 (sl) 2023-06-30
HRP20230538T1 (hr) 2023-08-04
RU2020101596A3 (es) 2022-03-22
RS64233B1 (sr) 2023-06-30
JP2020525020A (ja) 2020-08-27
MA49514A (fr) 2020-05-06
RU2020101596A (ru) 2021-07-27
MX2020000246A (es) 2020-08-10
CN116891534A (zh) 2023-10-17
AU2023204611A1 (en) 2023-08-03
ES2943020T3 (es) 2023-06-08
KR20200021987A (ko) 2020-03-02
SG11201911614XA (en) 2020-01-30
WO2019006046A2 (en) 2019-01-03
CO2019014684A2 (es) 2020-01-17

Similar Documents

Publication Publication Date Title
CL2019003843A1 (es) Partículas virales recombinantes con tropismo modificado y usos de estas para la introducción orientada de material genético en células humanas.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
PH12019500596A1 (en) Recombinant binding proteins and their use
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
CY1125392T1 (el) Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων
AR095437A1 (es) Proteínas de fusión comprendiendo porciones pdgf y vegf de unión y métodos para su uso
MX2020011788A (es) Acoplador trifuncional de antigeno de celulas t y metodos y usos del mismo.
MY185845A (en) Icos binding proteins
WO2014183071A3 (en) In vitro production of red blood cells with sortaggable proteins
GT201400302A (es) Celulas para producir iduronato-2-sulfatasa recombinante
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
EA201791918A1 (ru) Модификация белков клеток-хозяев
CY1121795T1 (el) Αντισωματα κατα toy cd52
MX2018009389A (es) Polipeptidos de union a la proteina a, anticuerpos anti-epha2 y metodos de uso de estos.
CL2019000019A1 (es) Anticuerpos con baja inmunogenicidad y uso de los mismos
PH12019550194A1 (en) Anti-ceacam1 antibody and use thereof
ES2526109R2 (es) Péptido y composición farmacéutica para el tratamiento del cáncer
MX2019010941A (es) Receptores de antigeno y usos de los mismos.
AR110347A1 (es) Anticuerpos anti-kremen2 y métodos para su uso
AR103810A1 (es) Modificación de proteína de célula hospedante